Aurobindo Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The purpose of the incorporation of this wholly owned subsidiary is to expand the biopharma products business in Europe.

The company has subscribed to an initial share capital of Euro 10,000, divided into 10,000 shares with a nominal value of Euro 1.00 each.

Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company?s consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24.

The scrip declined 3.61% to end at Rs 1,147.95 on the BSE.

Powered by Capital Market - Live News

Securities in F&O Ban:

Chambal Fertilisers & Chemicals, Hindustan Copper, Manappuram Finance, RBL Bank and Titagarh Rail Systems are banned from F&O trading on 27 May 2025.

Upcoming Results:

Life Insurance Corporation of India, Bharat Dynamics, Bosch, DCX Systems, Dynamatic Technologies, EID Parry India, Entero Healthcare Solutions, Esab India, Gujarat Fluorochemicals, Gateway Distriparks, Goodyear India, Hindustan Copper, ITI, JK Lakshmi Cement, Medplus Health Services, Minda Corporation, Info Edge (India), NMDC, V2 Retail will declare their results later today.

Stocks to Watch:

Aurobindo Pharma?s consolidated net profit fell 0.6% to Rs 903.47 crore despite of 11.9% increase in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24.

Akums Drugs & Pharmaceuticals reported consolidated net profit of Rs 147.62 crore in Q4 FY25 as compared with net loss of Rs 41.32 crore in Q4 FY24. Net sales jumped 11.8% YoY to Rs 1,055.55 crore in Q4 FY25.

Vadilal Industries? consolidated net profit declined 20.4% to Rs 22 crore in Q4 FY25 from Rs 27.64 crore in Q4 FY24. Net sales rose 9.2% YoY to Rs 274.47 crore during the quarter ended 31st March 2025.

Orchid Pharma reported a 32.4% decline in consolidated net profit to Rs 22.29 crore in Q4 FY25 as compared with Rs 32.96 crore in Q4 FY24. Net sales increased 9.4% YoY to Rs 237.48 crore in Q4 FY25.

Awfis Space Solutions? consolidated net profit soared 713.8% to Rs 11.23 crore on 46.2% increase in net sales to Rs 339.69 crore in Q4 FY25 over Q4 FY24.

Olectra Greentech reported a 53.2% increase in consolidated net profit to Rs 21 crore on 55.4% rise in net sales to Rs 448.92 crore in Q4 FY25 over Q4 FY24.

Powered by Capital Market - Live News

Net profit of Aurobindo Pharma declined 0.58% to Rs 903.47 crore in the quarter ended March 2025 as against Rs 908.75 crore during the previous quarter ended March 2024. Sales rose 11.87% to Rs 8381.12 crore in the quarter ended March 2025 as against Rs 7491.92 crore during the previous quarter ended March 2024.

For the full year,net profit rose 9.86% to Rs 3485.88 crore in the year ended March 2025 as against Rs 3172.97 crore during the previous year ended March 2024. Sales rose 9.31% to Rs 31378.13 crore in the year ended March 2025 as against Rs 28704.50 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 26 May 2025.

Powered by Capital Market - Live News